EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ewing Sarcoma in Infants and Children Under 2 Years of Age: A French Retrospective Study

Elodie Verdier iD, Nathalie Cozic, Marie-Dominique Tabone iD, Gaelle Pierron iD, Perrine Marec-Berard, Sarah Winter, Gabriel Revon-Rivière iD, Cyril Lervat, Dominique Plantaz, Marie-Pierre Castex, Gregory Guimard, Estelle Thebaud und 7 weitere

Pediatric Blood & Cancer · 2026

DOI: 10.1002/1545-5017.70632 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Elodie Verdier und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric and Adolescent Oncology, Gustave Roussy, Villejuif, France. Hauptthemen laut MEDLINE: Sarcoma, Ewing, Bone Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ligue contre le Cancer, Unicancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ewing sarcoma, the second most common primary bone cancer in children, requires intensive treatment that may lead to significant long‐term sequelae, particularly in infants. We retrospectively analyzed data from 1621 French patients treated between 1988 and 2015 within the EW88/93/97 or EE99 trials, focusing on 17 infants diagnosed before 24 months of age (1% of the cohort). Their outcomes were compared to the 1245 older pediatric patients (aged 2–18 years). Infant Ewing sarcomas were more frequently extraosseous (29% vs. 8%, p = 0.0037). Acute chemotherapy tolerance was comparable between infants and children under 2 years of age and older children. With a median follow‐up of 13.2 years (range: 7.8–15), adapted chemotherapy doses and reduced use of radiotherapy for local treatment, outcomes in infants were favorable, with the same rate of 88% for 5‐year disease‐free survival (DFS) and overall survival (OS). Two infants experienced localized recurrences, one of whom had undergone incomplete tumor resection without additional local treatment. At the last follow‐up, long‐term side effects were predominantly associated with local treatments, particularly surgery, rather than chemotherapy. However, given the young age of the patients, certain late toxicities (e.g., fertility impairment) remain unevaluated or could manifest in later years. Adapting chemotherapy doses to age and weight, combined with optimal local treatment, enables high survival rates in infants with Ewing sarcoma. Further monitoring is essential to assess long‐term sequelae as this population ages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sarcoma, EwingBone NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansRetrospective StudiesFemaleInfantChild, PreschoolMaleFranceFollow-Up StudiesAdolescentChildSurvival RateDisease-Free SurvivalPrognosis

Stichwörter der Autor:innen

Ewing sarcomainfantlong‐term follow‐up

Autor:innen und Institutionen

  • Department of Pediatric and Adolescent Oncology, Gustave Roussy, Villejuif, France.
  • Biostatistics and Epidemiology Department, Gustave Roussy, Villejuif, France.
  • Oncostat U1018, Inserm, Paris-Saclay University, League against Cancer Certified Team, Villejuif, France.
  • Department of Pediatric Hematology Immunology and Oncology, Armand Trousseau Hospital, Groupe Hospitalier Sorbonne Université, AP-HP, Paris, France.
  • Department of Genetics, Unité de Génétique Somatique, Institut Curie Hospital, Paris, France.
  • Pediatric Oncology Department, IHOPe - Institute of Pediatric Hematology and Oncology, Lyon, France.

ORCID-Profile: Elodie Verdier, Marie-Dominique Tabone, Gaelle Pierron, Gabriel Revon-Rivière, Natacha Entz-Werle, Marta Jimenez, Nathalie Gaspar

Förderung

  • Ligue contre le Cancer
  • Unicancer

Zitieren

APA

Verdier, E., Cozic, N., Tabone, M. D., Pierron, G., Marec-Berard, P., Winter, S., Revon-Rivière, G., Lervat, C., Plantaz, D., Castex, M. P., Guimard, G., Thebaud, E., Proust, S., Saumet, L., Entz-Werle, N., Taque, S., Vérité, C., Jimenez, M., & Gaspar, N. (2026). Ewing Sarcoma in Infants and Children Under 2 Years of Age: A French Retrospective Study. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70632

Vancouver

Verdier E, Cozic N, Tabone MD, Pierron G, Marec-Berard P, Winter S, et al. Ewing Sarcoma in Infants and Children Under 2 Years of Age: A French Retrospective Study. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70632

BibTeX
@article{Verdier2026,
  author = {Verdier, Elodie and Cozic, Nathalie and Tabone, Marie-Dominique and Pierron, Gaelle and Marec-Berard, Perrine and Winter, Sarah and Revon-Rivière, Gabriel and Lervat, Cyril and Plantaz, Dominique and Castex, Marie-Pierre and Guimard, Gregory and Thebaud, Estelle and Proust, Stephanie and Saumet, Laure and Entz-Werle, Natacha and Taque, Sophie and Vérité, Cécile and Jimenez, Marta and Gaspar, Nathalie},
  title = {Ewing Sarcoma in Infants and Children Under 2 Years of Age: A French Retrospective Study},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  doi = {10.1002/1545-5017.70632}
}
Kostenlos starten →